使用纯音听力测定法和畸变产物耳声发射评估血液透析对听力的影响。

The effect of hemodialysis on hearing using pure-tone audiometry and distortion-product otoacoustic emissions.

作者信息

Ozturan O, Lam S

机构信息

Department of Otolaryngology, Inonu University, School of Medicine, Malatya,

出版信息

ORL J Otorhinolaryngol Relat Spec. 1998 Nov-Dec;60(6):306-13. doi: 10.1159/000027615.

DOI:10.1159/000027615

PMID:9742277

Abstract

Patients under treatment of hemodialysis (HD) frequently exhibit some degree of sensorineural hearing loss. Fifteen subjects and 10 controls were tested by using pure-tone audiometry (PTA) and distortion-product otoacoustic emissions (DPOAEs) before and after a HD treatment. Other parameters (blood pressure, body weight, blood chemistries) were also evaluated before and after HD: The purpose of this study was to determine the acute effect of HD on hearing level by measuring PTA and DPOAE before and after one HD session. The results from PTA and DPOAE testings showed that hearing was unaffected by HD. However, all 15 subjects revealed significantly poorer hearing, especially in the higher frequencies, compared to that of the controls (p < 0.0001). It was concluded then that HD is a safe treatment, and that the sensorineural hearing loss in these patients may be attributed to the preexisting renal disease.

摘要

接受血液透析（HD）治疗的患者经常会出现一定程度的感音神经性听力损失。在一次HD治疗前后，使用纯音听力测定法（PTA）和畸变产物耳声发射（DPOAE）对15名受试者和10名对照者进行了测试。在HD前后还评估了其他参数（血压、体重、血液化学指标）：本研究的目的是通过测量一次HD治疗前后的PTA和DPOAE来确定HD对听力水平的急性影响。PTA和DPOAE测试结果表明，HD对听力没有影响。然而，与对照组相比，所有15名受试者的听力明显较差，尤其是在高频方面（p < 0.0001）。因此得出结论，HD是一种安全的治疗方法，这些患者的感音神经性听力损失可能归因于先前存在的肾脏疾病。